Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

NADH-cytochrome b5 reductase 3

6

Nitric oxide synthase (inducible and endothelial)

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

7

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

6

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Alzheimer’s disease

6

Cancer

6

Dermatologic infections

6

Ifosfamide-induced encelophaty

6

Methemoglobinemia

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Diagnostic

6

Preventing

6

Primary

6

Curative

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

BASF

6

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

7

FDA UNII

7

PUBCHEM

7

EPA CompTox

5

EVMPD

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

VARIOUS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ALL OTHER THERAPEUTIC PRODUCTS

2

DIAGNOSTIC AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ALL OTHER THERAPEUTIC PRODUCTS

2

OTHER DIAGNOSTIC AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antidotes

2

Tests for gastric secretion

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

METHYLENE BLUE CATION

ZMZ79891ZH

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

NADH-cytochrome b5 reductase 3

Nitric oxide synthase (inducible and endothelial)

Conditions:

Ifosfamide-induced encelophaty

Methemoglobinemia

Dermatologic infections

Alzheimer’s disease

Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. ...

Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.

ZINC SALICYLATE

96OQ2F972S

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Acne-prone skin

Zinc Salicylate is an antiseptic, astringent and source of zinc for personal care products such as dusting powders and antiperspirants. It is also used in the production of carbonless copy paper as a color developer.

METHYLENE BLUE PENTAHYDRATE

TJ8EMU6QT3

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

NADH-cytochrome b5 reductase 3

Nitric oxide synthase (inducible and endothelial)

Conditions:

Ifosfamide-induced encelophaty

Methemoglobinemia

Dermatologic infections

Alzheimer’s disease

Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. ...

Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.

METHYLENE BLUE MONOHYDRATE

O3YJW1TB3C

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

NADH-cytochrome b5 reductase 3

Nitric oxide synthase (inducible and endothelial)

Conditions:

Ifosfamide-induced encelophaty

Methemoglobinemia

Dermatologic infections

Alzheimer’s disease

Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. ...

Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.

METHYLENE BLUE HYDROXIDE

3EAZ4M2MHL

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

NADH-cytochrome b5 reductase 3

Nitric oxide synthase (inducible and endothelial)

Conditions:

Ifosfamide-induced encelophaty

Methemoglobinemia

Dermatologic infections

Alzheimer’s disease

Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. ...

Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.

METHYLENE BLUE ANHYDROUS

8NAP7826UB

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

NADH-cytochrome b5 reductase 3

Nitric oxide synthase (inducible and endothelial)

Conditions:

Ifosfamide-induced encelophaty

Methemoglobinemia

Dermatologic infections

Alzheimer’s disease

Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. ...

Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.

METHYLENE BLUE

T42P99266K

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

NADH-cytochrome b5 reductase 3

Nitric oxide synthase (inducible and endothelial)

Conditions:

Ifosfamide-induced encelophaty

Methemoglobinemia

Dermatologic infections

Alzheimer’s disease

Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. ...

Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1